The efficacy of allogeneic, haemopoietic stem cell transplantation (HSCT) is limited by concomitant toxicity. This has led to the development of less toxic, reduced intensity conditioning (RIC) protocols, whose therapeutic benefit is largely related to an associated, immunity-mediated graft-versus-malignancy effect rather than by the cytotoxic treatment itself. Murine HSCT models suggests that acute graft-versus-host disease (GVHD) increases with the intensification of the conditioning regimen mediated by loss of integrity of the gut mucosa barrier. The present study was undertaken to investigate gastro-intestinal (GI) permeability during allogeneic HSCT with RIC. In 17 patients (myeloablative conditioning in nine, RIC in eight), intestinal permeability was assessed by a 51 Cr-EDTA absorption test before the start of cytotoxic treatment the day before stem cell infusion (day −1) and 4, 7 and 14 days after stem cell infusion. Patients receiving RIC did not develop any significant increase in intestinal permeability during the transplantation course but in myeloablatively conditioned patients there was a significant increase in intestinal permeability the day before the stem cell infusion (P Ͻ 0.005), on day 4 (P Ͻ 0.005), on day 7 (P Ͻ 0.01) and on day 14 (P Ͻ 0.005) after stem cell infusion, compared with the baseline. Myeloablative conditioning also revealed increased intestinal permeability on day 7 compared with the RIC (P Ͻ 0.05). The finding of preserved intestinal-barrier function during allogeneic HSCT with RIC is discussed, with reference to the hypothesis that GI tract damage may be an important initiating event of GVHD. Bone Marrow Transplantation (2001) 28, 737-742.
GI toxicity is currently the dose-limiting factor for highdose treatment with autologous or allogeneic, haemopoietic stem cell support. It is known from former studies that there is a disruption of the gut mucosa barrier with myeloablative HSCT, 1, 2 , yielding a potential means of entry of bacteria and/or endotoxin into the systemic circulation. 3 Endotoxin is a potent stimulator of the release of inflammatory cytokines, which in their turn are important mediators of clinical [4] [5] [6] and experimental [7] [8] [9] GVHD. In murine models it has been demonstrated that an intensification of the conditioning treatment caused aggravated intestinal damage, increased translocation of endotoxin and a subsequent increase in GVHD severity. 8 Furthermore, since these murine HSCT models allow tight control of the variables upon which GVHD depends, diminished GVHD has been achieved with different strategies designed to protect intestinal barrier integrity. 10, 11 Recently, a novel approach has been introduced in the treatment of haematological malignancies [12] [13] [14] and some solid tumours 15 -allogeneic, haemopoietic stem cell transplantation after reduced conditioning (RIC) -with which curative potential is believed to be mediated to a greater extent by the immunologically mediated, graft-versusleukaemia/tumour effect rather than by the chemotherapy itself. Therefore this approach may offer a less toxic alternative for patients not eligible for high-dose therapy. Clinical GI toxicity of RIC transplants has been reported as being very moderate. 12, 13 Despite that, severe GVHD has been reported with this approach. However, prophylaxis against GVHD has generally been less intensive, tapered quickly and occasionally followed by donor lymphocyte infusion (DLI) in order to induce a GVL effect, with subsequent increased risk of inducing severe GVHD. 12 Thus, it has been difficult to make any comments on the influence on prevalence and severity of GVHD of the reduced tissue damage with this approach. However, preclinical studies offer good reasons for the assumption that allogeneic transplantation with RIC may cause less damage to the gut mucosa barrier than myeloablative conditioning. 13, 14 The aim of the present study was therefore to investigate intestinal barrier function in patients undergoing allogeneic HSCT with RIC.
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Patients and methods
Patients
In this prospective, non-randomised study, 17 patients undergoing allogeneic HSCT (RIC in eight, myeloablative conditioning in nine) at the Department of Haematology, Sahlgrenska University Hospital, Gothenburg, Sweden, were included between October 1998 and March 2000. Another 15 patients (three RIC, 12 myeloablative conditioned) underwent allogeneic HSCT during the same period but were not enrolled into the study (three patients declined enrollment and in 12 patients enrollment was unintentionally missed). Baseline clinical characteristics did not differ between patients included and excluded (data not shown).
Two patients were offered a transplant with RIC since they were regarded as high risk for a myeloablative allograft (one 63-year-old male with CML/CP3 after an autograft and one 53-year-old female with AML/CR2 with an unrelated donor). Four patients (all CML/CP1) underwent allografting with RIC after informed choice. Two patients with metastatic renal carcinoma were offered an allogeneic allograft with RIC as part of a clinical protocol.
Myeloablative conditioning consisted of cyclophosphamide and total body irradiation (TBI) given to patients with leukaemia, with the addition of anti-T lymphocyte globulin (ATG) to prevent graft rejection when stem cells from an unrelated donor were used. The reduced intensityconditioning regimens consisted of fludarabine/ busulphan/ATG and fludarabine/cyclophosphamide/ATG given to patients with leukaemia and renal carcinoma, respectively.
GVHD prophylaxis consisted of cyclosporine (CsA) alone, administered at 4 mg/kg/day and at 5 mg/kg/day to patients with renal carcinoma and leukaemia, respectively. In addition, methotrexate was administered at 15 mg/m 2 on day 1 and at 10 mg/m 2 on days 3, 6 and 11 to all myeloablative transplant patients and to two of the RIC patients. Further details regarding patient characteristics and conditioning are given in Table 1 .
The study protocol was approved by the Ethical Committee and the Isotope Committee of Sahlgrenska University Hospital and all the patients gave informed, written consent before inclusion.
Methods
GI permeability was assessed by a 51
Cr-EDTA absorption test 16 before the start of cytotoxic treatment, 1 day prior to stem cell infusion (after the termination of the cytotoxic treatment) and 4, 7 and 14 days after stem cell infusion. The 24-h urinary excretion of the 51 Cr-EDTA was expressed as a percentage of the dose given orally.
During the same period, GI toxicity and acute GVHD were graded prospectively, according to the WHO criteria 17 and the international guidelines, 18 respectively. All patients received the same prophylactic antibiotics (orally administered ciprofloxacin 1000 mg/day, fluconazole 400 mg/day and aciclovir 3200 mg/day) throughout the study period and anti-emetic therapy (ondansetron) during , cyclophosphamide 30 mg/kg/day for 2 days (−5 to −4) and ATG 5 mg/kg/day for 3 consecutive days (−3 to −1); CsA = cyclosporine; AML = acute myeloid leukaemia; CML = chronic myeloid leukaemia; ALL = acute lymphoblastic leukaemia; CR 1 = first complete remission; CR 2 = second complete remission; CP 1 = first chronic phase; CP у2 = second or later chronic phase; BM = bone marrow; PBSC = peripheral blood stem cells.
conditioning. Total parenteral nutrition (TPN) was generally started when the daily, oral, caloric intake decreased below 50% of the basal needs and was tapered and stopped when the daily caloric intake exceeded 50% of the basal needs. Glutamine enriched TPN (Glavamin; Fresenius Kabi, Uppsala, Sweden, 0.1-0.2 g/kg body weight per day of glutamine) was given to one patient in the myeloablative group, but besides that, the patients did not receive any other agent thought to ameliorate GI toxicity (for example IL-11, KGF or amifostine).
Statistics
Data are expressed as means ± s.d. The Mann-Whitney U test was used for significance calculations of differences in 24-h urinary excretion between groups. A P value Ͻ0.05 was considered statistically significant.
Results
Intestinal permeability
Patients receiving RIC did not develop any significant increase in intestinal permeability at any measurement point during the transplantation course compared with the baseline. In patients who received traditional, myeloablative conditioning there was a significant increase in intestinal permeability the day before the stem cell infusion (P Ͻ 0.005), on day 4 (P Ͻ 0.005), on day 7 (P Ͻ 0.01) and on day 14 (P Ͻ 0.005) after stem-cell infusion, compared with the baseline and on day 7 (p 0.05) compared with patients receiving RIC. Baseline permeability values were within the normal range in both the study groups but were significantly increased in patients who received RIC, compared with patients who received myeloablative conditioning ( Table 2) .
Clinical intestinal toxicity
Clinical GI toxicity, according to the WHO criteria was more pronounced among the myeloablated patients. All patients in the myeloablated group (n = 9) were in need of therapy against GI toxicity (nausea/vomiting, oral pains and/or diarrhoea) during the transplantation course but only two out of nine RIC transplant patients needed such therapy (P Ͻ 0.01, Fisher's exact test). In addition, the need for total parenteral nutrition (TPN) was less pronounced among the RIC patients, compared with the myeloablated patients (Table 3) .
Non-intestinal (clinical) outcome
Inflammatory response (expressed as CRP elevation) and haematological toxicity were more pronounced among myeloablated patients and the treatment time with intravenous antibiotics was significantly longer in this group. No significant differences regarding the time to onset, prevalence and severity of acute GVHD were identified between the groups (Table 3) . Table 2 Cr-EDTA resorption on the different measurement days (% ± s.d.)
Day
Myeloablative cond. The number of patients. RIC = reduced intensity conditioning; NS = not significant. 
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Discussion
The main finding in the present study was not the demonstration of a disruption of the intestinal barrier with myeloablative conditioning, since this is by now a well-documented phenomenon. 1, 2 Neither was the main finding the confirmation of earlier reports in which HSCT with RIC have been associated with less GI toxicity, as assessed by clinical scoring, 12 compared with traditional, myeloablative transplantation. Instead, the novel finding was the absence even of a subclinical increase in intestinal permeability as assessed by the 51 Cr-EDTA resorption test, among patients who received RIC. There may be several reasons for this, such as less intensive conditioning and the fact that most patients were able to continue enteral feeding during the transplantation course.
Objections may be raised against the need for a trial comparing intestinal barrier function between these two approaches since the difference in clinical intestinal toxicity between them is quite obvious. However, in this context, it has to be emphasised that absence of clinical toxicity is by no means equal to a preservation of intestinal barrier function. There are several reports of intestinal barrier disruption with chemotherapy, without the presence of corresponding clinical toxicity.
19-21
Methodological considerations
With techniques evaluating intestinal permeability, both pre-and postmucosal factors such as gastric emptying, intestinal transit time and renal function, may influence test results. This led to the formulation of the principle of differential urinary excretion of two test substances administered simultaneously. 22 The principle is based on the fact that these variables, which do not reflect intestinal permeability, affect the two test substances equally and therefore any change in these variables will not affect the urinary excretion ratio between the two test substances. However, the present study evaluates intestinal permeability using only one test substance ( 51 Cr-EDTA). Besides the safety and simplicity of the test, there were several additional reasons for this. Firstly, a previous trial to evaluate intestinal permeability, using sugar probes in patients undergoing HSCT, revealed that two-thirds of the patients were unable to complete the tests. 1 Another disadvantage of using sugar probes is that they are subject to tissue and bacterial degradation, 23 which restricts the timing of urine collection to about 5 h. With 51 Cr-EDTA there is the possibility of increasing the test sensitivity by prolonging the urine collection time. 16, 24 Thus, the extended urine collection period used in the present study may have reduced the influence of variations in gastric emptying, intestinal transit time and renal function. It is true, that the possibility cannot be ruled out that using another permeability marker may have made it possible to detect an intestinal barrier dysfunction even in the RIC group. However, the marker used ( 51 Cr-EDTA) has been used to demonstrate increased intestinal permeability in myeloablated BMT patients in previous trials 1, 2 and when discussing the hypothesis that intestinal barrier dysfunction may be an initial event in GVHD, the difference between the two conditioning regimens used seems to be far more relevant rather than the possibility that there might have been a slight intestinal barrier disruption among RIC patients, not detected by the test. Furthermore, 51 Cr-EDTA has been shown to have the potential for detecting intestinal barrier dysfunction even in asymptomatic patients with intestinal diseases such as coeliac disease in remission. 16 The populations studied were homogenous in terms of age, known intestinal diseases and GI symptoms present at time of inclusion. There was a difference between the groups regarding baseline intestinal permeability but all baseline values in both the groups paralleled those of the healthy volunteers reported by others using the same technique. 24 In addition, since permeability was lower in patients assigned to myeloablative conditioning, it is unlikely that this difference in baseline permeability would have been responsible for the difference between the groups later on during the transplantation course.
Gut damage and GVHD
In a murine myeloablative HSCT model inducing 100% donor chimerism, reduced dose intensity of conditioning caused less intestinal toxicity and a subsequent reduction in acute GVHD. 8 Such a finding indicates that damage to the GI tract may amplify systemic acute GVHD severity. 25 This hypothesis proposes that endotoxin from the gut may leak through the damaged bowel wall and stimulate endothelial cells and/or macrophages to produce cytokines 26 which, in their turn 7, 27 upregulate adhesion molecules 28 and major histocompatibility complex (MHC) antigens, 29, 30 thereby enhancing the recognition of host MHC or minor histocompatibility antigens by mature, donor T cells.
However, using clinical data it has been difficult to demonstrate this correlation between dose intensity of the conditioning and subsequent GVHD severity. Allogeneic transplants with RIC have been associated with very moderate clinical GI toxicity. Despite that, it has been difficult to make any comments concerning influence on prevalence and severity of GVHD of this approach since prophylaxis against GVHD generally has been less intensive, tapered quickly and occasionally followed by donor lymphocyte infusion, in order to induce a GVL/GVT effect, with a subsequent increased risk of inducing severe GVHD.
There are alternative explanations, besides reduced tissue or GI damage, of why RIC should reduce GVHD severity. This includes survival of persisting host cells, following RIC, therefore facilitating the development of mixed, donor-host chimerism, which has been associated with tolerance of donor T cells to host tissues and a subsequently decreased probability of GVHD. [31] [32] [33] Hence, owing to the multifactorial pathophysiology of GVHD it may be difficult to translate murine data into the clinical situation. Provided that these findings, which suggest that GVHD severity partly depends on GI toxicity is correct, the finding in the present study, that the intestinal barrier was preserved with RIC, may suggest that probability of developing GVHD should be reduced with this approach.
Gut protective strategies and GVHD
It was beyond the aim of the present study to compare prevalence and severity of acute GVHD between the study groups. Even in larger trials, it has been difficult to demonstrate any clear relationship between conditioning intensity and GVHD severity, mainly because it has been difficult to distinguish the influence of conditioning intensity from that of the intensity of GVHD prophylaxis. [34] [35] [36] On the other hand, murine HSCT models, which allow tight control of the variables on which GVHD depends, have revealed diminished GVHD with different strategies designed to protect intestinal barrier integrity. For example, the administration of keratinocyte growth factor (KGF) before autologous HSCT dramatically protected the gut epithelium from injury by lethal chemotherapy. 37 The protection appears to result from a potent trophic effect on intestinal epithelium 38 and from improved survival of crypt stem cells. 39 Accordingly, in an allogeneic murine HSCT model the administration of KGF before the conditioning, reduced mortality rate as well as GVHD severity. 10 Interleukin-11 (IL-11) is another agent which has shown gut-protective properties in models of gut injury after chemotherapy and radiation. 40 In experimental studies, IL-11 almost completely prevented GVHD of the small bowel and reduced serum endotoxin levels after allogeneic HSCT by 80%.
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Since murine data revealed aggravated GVHD with increased intestinal injury, the main finding in the present study, that of preserved intestinal integrity with RIC, may indicate a potentially reduced risk of GVHD with this approach.
The relationship between gut damage and GVHD in the clinical situation may be further assess in randomised trials to assess agents designed to protect the GI tract from toxicity induced by myeloablative conditioning. clinical assistance. This work was financially supported by the Göteborg Medical Society, the funds of Jubileumskliniken at Sahlgrenska University Hospital and by the funds of Assar Gabrielsson.
